Runben Biotechnology Co., Ltd. (SHA:603193)
China
· Delayed Price · Currency is CNY 35.84
-1.19 (-3.21%)
Jun 13, 2025, 2:45 PM CST
Runben Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | 308.89 | 300.16 | 226.03 | 160.04 | 120.65 | 94.71 | Upgrade
|
| Depreciation & Amortization | 20.91 | 20.91 | 21.87 | 19.77 | 10.53 | 8.01 | Upgrade
|
| Other Amortization | 0.37 | 0.37 | 0.11 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.51 | 0.51 | -0.07 | -0.05 | -0 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | -3.5 | -3.5 | - | 0 | 0.02 | 0 | Upgrade
|
| Loss (Gain) From Sale of Investments | -3.86 | -3.86 | -0.84 | -2.05 | -1.96 | -1.11 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.47 | 0.47 | 0.2 | -0.02 | -0 | 0.02 | Upgrade
|
| Other Operating Activities | -21.45 | -26.05 | -11.5 | 1.62 | 2.71 | 0.79 | Upgrade
|
| Change in Accounts Receivable | -23.06 | -23.06 | 10.38 | -2.43 | -6.44 | -1.98 | Upgrade
|
| Change in Inventory | -27.48 | -27.48 | 7.39 | -46.95 | -14.09 | -16.43 | Upgrade
|
| Change in Accounts Payable | 41.72 | 41.72 | 3.71 | 43.2 | 27.73 | 3.32 | Upgrade
|
| Change in Other Net Operating Assets | 0.64 | 0.64 | 1.42 | 0.9 | 2.68 | 0.07 | Upgrade
|
| Operating Cash Flow | 270.56 | 257.24 | 252.52 | 165.32 | 138.65 | 87.14 | Upgrade
|
| Operating Cash Flow Growth | 5.03% | 1.87% | 52.74% | 19.24% | 59.12% | 40.74% | Upgrade
|
| Capital Expenditures | -83.52 | -74.22 | -13.65 | -40.65 | -152.03 | -58.2 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.1 | 0.1 | 0 | 0.14 | 0 | - | Upgrade
|
| Investment in Securities | -135.22 | -263.83 | -1,301 | 48 | -14.43 | -17.52 | Upgrade
|
| Other Investing Activities | 43.28 | 41.03 | 4.73 | 2.05 | 2.32 | 0.75 | Upgrade
|
| Investing Cash Flow | -175.37 | -296.92 | -1,310 | 9.53 | -164.14 | -74.98 | Upgrade
|
| Long-Term Debt Repaid | - | -1.52 | -2.34 | -2.92 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -1.52 | -1.52 | -2.34 | -2.92 | - | - | Upgrade
|
| Issuance of Common Stock | - | - | 995.48 | - | 225.66 | 17.99 | Upgrade
|
| Common Dividends Paid | -136.04 | -136.04 | - | -3.44 | -30.95 | - | Upgrade
|
| Other Financing Activities | - | - | -20.3 | -3.03 | -6.32 | -1.74 | Upgrade
|
| Financing Cash Flow | -137.56 | -137.56 | 972.84 | -9.39 | 188.39 | 16.25 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0 | 0 | - | - | 0.24 | - | Upgrade
|
| Net Cash Flow | -42.36 | -177.24 | -84.32 | 165.47 | 163.15 | 28.41 | Upgrade
|
| Free Cash Flow | 187.04 | 183.02 | 238.87 | 124.67 | -13.38 | 28.93 | Upgrade
|
| Free Cash Flow Growth | -24.71% | -23.38% | 91.60% | - | - | -33.37% | Upgrade
|
| Free Cash Flow Margin | 13.44% | 13.88% | 23.13% | 14.56% | -2.30% | 6.53% | Upgrade
|
| Free Cash Flow Per Share | 0.46 | 0.45 | 0.68 | 0.37 | -0.04 | 0.10 | Upgrade
|
| Cash Income Tax Paid | 166.13 | 162.07 | 127.8 | 77.47 | 58.49 | 49.7 | Upgrade
|
| Levered Free Cash Flow | 1,557 | 134.87 | 180.69 | 59.89 | -30.47 | -6.14 | Upgrade
|
| Unlevered Free Cash Flow | 1,557 | 134.96 | 180.85 | 60.16 | -30.13 | -6.14 | Upgrade
|
| Change in Net Working Capital | -1,415 | 5.35 | -19.47 | 30.69 | -27.07 | 22.78 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.